Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Atossa Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$2.46

-0.12 (-4.84%)

C 45Pipeline Score Fair Value Pharma · Clinical
Market Cap
41.77 M
EPS
-4.37
P/E Ratio
-1.11 $
Value Trade
212.74 K
SEC Financials
Q1 2026

  • Dilution Risk

    60%

  • R&D Expenses

    4.78 M

  • Operating CF

    -9.58 M

  • Total Assets

    37.94 M

  • Total Liabilities

    7.46 M

  • Equity

    30.49 M

  • D/E Ratio

    12,345

-2.94 %
Week
-15.5 %
1 Month
13.24 %
3 Month
-56.1 %
6 Month
-89.86 %
5 Year
-99.96 %
All Time
Cash Data
Caution

  • Cash Position

    31.72 M

  • Monthly Burn

    3.19 M

  • Runway

    8.8 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 8, 2026
Overview
Volume
644.75 K
52 Week Range
3.76 - 19.35
% held by Insiders
1.76 %
% held by Institutions
18.8 %
Enterprise Value
9.94 M
Total Shares
8.61 M
Short %
5.22 %
Float Shares
7.68 M
Company Description
HQ: 1448 NW MARKET STREET, SEATTLE...
Founded:2008
Employees:14
https://www.atossatherapeutics...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C45
Pipeline Score
$100M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
2.4x
rNPV / MCap
Top 68%
Micro Cap
(rank 291 of 905)
Percentile Rank
Atossa Therapeutics, Inc. carries a moderate pipeline score (45/100), with $3.9B risk-adjusted pipeline value, led by -endoxifen in Breast Neoplasms (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
-endoxifen
Small molecule		Breast NeoplasmsPhase 2NCT0560700438% $3.5B RECRUITING 87 STALLED C (42) Apr 1, 2027MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
(Z)-endoxifen
metastatic breast cancer
Phase 2
2025-07-29
(Z)-endoxifen
metastatic breast cancer
Phase 2
2025-07-29
(Z)-endoxifen
metastatic breast cancer
Phase 2
2025-07-29
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ATOS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ATOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ATOS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ATOS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Atossa Therapeutics, Inc. (ATOS) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ATOS ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Breast Cancer #25 of 94 PHASE 2 -endoxifen + goserelin
AZN MRK LLY
$10.85B 0.85 FOLLOWER